Form 4: SUPN Officer Acquires 1,250 PSUs, Boosts Holdings

Supernus Pharmaceuticals' Sr. VP of IP and CSO, Padmanabh P. Bhatt, acquired 1,250 Performance Share Units and increased common stock holdings to 13,049 shares.

Summary

• Padmanabh P. Bhatt, Sr. VP of IP and CSO of Supernus Pharmaceuticals, Inc. (SUPN), reported changes in beneficial ownership.
• Bhatt acquired 1,250 Performance Share Units (PSUs) on August 7, 2025, which vested upon achievement of individual performance objectives.
• These PSUs convert into 1,250 shares of common stock.
• Following the reported transactions, Bhatt directly owns 1,250 derivative securities (PSUs) and 13,049 shares of common stock.
• The common stock holdings include 345 shares acquired through the Issuer's Employee Stock Purchase Plan.

Sentiment

Score: 7

Explanation: The filing indicates an increase in executive ownership through equity compensation, which is generally a positive signal of alignment between management and shareholder interests. The transaction is routine for executive compensation.

Positives

• Insider acquisition of 1,250 Performance Share Units indicates management confidence in future performance.
• Increased beneficial ownership by a key executive aligns their interests with shareholders.

Future Outlook

NA

Industry Context

This filing reflects routine executive equity compensation and vesting within the pharmaceutical industry, a common practice to incentivize long-term performance and align executive interests with company success.

Comparison to Industry Standards

• The use of Performance Share Units (PSUs) with performance-based vesting is a standard practice in the pharmaceutical and biotechnology sectors for executive compensation, aligning incentives with strategic goals.
• The reported beneficial ownership of 13,049 common shares and 1,250 PSUs for a Senior VP of IP and CSO is within typical ranges for executives at mid-cap pharmaceutical companies like Supernus Pharmaceuticals, Inc., comparable to similar equity holdings seen at companies such as Acadia Pharmaceuticals (ACAD) or Neurocrine Biosciences (NBIX) for executives at similar levels.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with shareholder value due to higher equity ownership.
• Employees: Reflects standard employee stock purchase plan and performance-based compensation practices.

Key Dates

Recommendation

This Form 4 filing reports a routine vesting of performance share units and an increase in an executive's beneficial ownership, which is generally a positive signal of management alignment. However, it does not provide new fundamental information about the company's financial performance or strategic direction that would warrant a 'buy' or 'sell' recommendation. It's a standard disclosure of executive compensation. Investors should hold and monitor for broader company news and financial results.

Keywords

Supernus Pharmaceuticals, SUPN, Form 4, Insider Trading, Performance Share Units, Equity Compensation, Executive Holdings, Biotechnology, Pharmaceuticals